Spinal Muscular Atrophy in the Treatment Era.
Multidisciplinary care
Newborn screen
Nusinersen
Onasemnogene abeparvovec-xioi
Spinal muscular atrophy
Journal
Neurologic clinics
ISSN: 1557-9875
Titre abrégé: Neurol Clin
Pays: United States
ID NLM: 8219232
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
entrez:
25
7
2020
pubmed:
25
7
2020
medline:
18
11
2020
Statut:
ppublish
Résumé
Spinal muscular atrophy is an autosomal-recessive degenerative neuromuscular disease that has historically been categorized into 5 types based on the individual's best functional ability. Two rather remarkable treatments have recently been approved for commercial use, and both have markedly changed the natural history of this disease. Here the authors report several cases of individuals, ranging from infants to adults, to highlight diagnostic considerations, along with initial and long-term treatment considerations in these individuals who now have the potential for stabilization to significant improvement in functional outcomes.
Identifiants
pubmed: 32703464
pii: S0733-8619(20)30023-2
doi: 10.1016/j.ncl.2020.03.002
pii:
doi:
Substances chimiques
Oligonucleotides
0
nusinersen
5Z9SP3X666
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
505-518Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.